Biotech Values

[biotplaya]

Hi Dew,

<At two months from baseline (one month from the end of treatment), 33% of Squalamine patients in the Mexican trial had improved vision, defined as a gain of 3+ lines (15 letters) relative to baseline. At four months from baseline (three months from the end of treatment), 26% of Squalamine patients in the Mexican trial still had improved vision, using the same definition>

my amateurish observation tells me 33% to 26% is not the way to go, especially when compared to Lucentis 45%,34%. Is there more to look at than this? Have you lost confidence in GENR to come through? Thank you.